Insider trading

Period: 120 months Stock: ACET Minimum amount: $100K × + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

42 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

42 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

42 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

42 decisions over 120 months Remove this filter
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
42 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
42 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

42 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
8 Apr 2026
ORBIMED ADVISORS LLC 10% owner · indirect
Sold at will 2×
$468.08K 72,939 at 6.42
100%
Sold half or more
7 Apr 2026
ORBIMED ADVISORS LLC 10% owner · indirect
Sold at will 2×
$206.77K 31,719 at 6.52
49.4%
Not planned
20 Feb 2026
RA CAPITAL MANAGEMENT, L.P. 10% owner · indirect
Bought
$543.44K 74,751 at 7.27
6.7%
Largest buy in 3 yrs
19 Feb 2026
RA CAPITAL MANAGEMENT, L.P. 10% owner · indirect
Bought
$535.47K 74,268 at 7.21
7.2%
Largest buy in 3 yrs
18 Feb 2026
RA CAPITAL MANAGEMENT, L.P. 10% owner · indirect
Bought
$525.02K 74,577 at 7.04
7.8%
First buy on file
8 Oct 2025
ORBIMED ADVISORS LLC 10% owner · indirect
Bought 2×
$5.00M 5,000,000 at 1.00
124%
+124% of stake
25 Jan 2024
GORDON CARL L Director · indirect
Bought 3×
$7.50M 3,125,000 at 2.40
71.0%
Largest buy in 3 yrs
25 Jan 2024
ORBIMED ADVISORS LLC Director · indirect
Bought 3×
$7.50M 3,125,000 at 2.40
71.0%
Largest buy in 3 yrs
27 Jun 2023
GORDON CARL L Director · indirect
Bought 4×
$1.83M 875,000 at 2.09
18.2%
First buy on file
27 Jun 2023
ORBIMED ADVISORS LLC Director · indirect
Bought 4×
$1.83M 875,000 at 2.09
18.2%
First buy on file
10 Nov 2022
Schor Chen President & CEO · indirect
Sold, plan not stated
$601.92K 30,000 at 20.06
36.0%
10 Nov 2022
Schor Chen President & CEO
Sold, plan not stated
$209.32K 9,955 at 21.03
9.8%
10 Nov 2022
Aftab Blake Chief Scientific Officer
Sold, plan not stated
$146.31K 6,967 at 21.00
19.8%
7 Nov 2022
Schor Chen President & CEO · indirect
Sold, plan not stated
$571.49K 30,000 at 19.05
26.4%
3 Nov 2022
Schor Chen President & CEO · indirect
Sold, plan not stated
$447.72K 24,813 at 18.04
17.9%
19 Oct 2022
Aftab Blake Chief Scientific Officer
Sold, plan not stated
$131.25K 8,067 at 16.27
18.7%
12 Sep 2022
Schor Chen President & CEO · indirect
Sold, plan not stated 2×
$1.12M 66,947 at 16.77
100%
Sold half or more
9 Sep 2022
Schor Chen President & CEO · indirect
Sold, plan not stated
$133.60K 8,094 at 16.51
10.8%
3 Aug 2022
Aftab Blake Chief Scientific Officer
Sold, plan not stated
$125.42K 6,968 at 18.00
15.2%
1 Aug 2022
Aftab Blake Chief Scientific Officer
Sold, plan not stated
$115.95K 6,968 at 16.64
13.2%
4 Apr 2022
Galimi Francesco SVP & Chief Medical Officer
Sold, plan not stated 3×
$167.56K 7,979 at 21.00
11.8%
1 Apr 2022
Galimi Francesco SVP & Chief Medical Officer
Sold, plan not stated
$160.04K 7,621 at 21.00
11.3%
9 Feb 2022
Jakobovits Aya Director · indirect
Sold, plan not stated 2×
$112.24K 8,000 at 14.03
2.2%
3 Jan 2022
Jakobovits Aya Director · indirect
Sold, plan not stated 2×
$216.26K 12,000 at 18.02
3.2%
8 Dec 2021
Sinclair Andrew Director · indirect
Bought
$7.00M 500,000 at 14.00
30.5%
First buy on file
16 Jun 2021
Schor Chen President & CEO · indirect
Sold, plan not stated 2×
$173.44K 16,466 at 10.53
18.0%
3 Jun 2021
Schor Chen President & CEO · indirect
Sold, plan not stated 2×
$198.50K 16,466 at 12.06
16.7%
19 May 2021
Schor Chen President & CEO · indirect
Sold, plan not stated 4×
$221.44K 16,466 at 13.45
15.5%
12 May 2021
Jakobovits Aya Director · indirect
Sold, plan not stated 2×
$132.33K 10,000 at 13.23
4.3%
5 May 2021
Schor Chen President & CEO · indirect
Sold, plan not stated 4×
$234.22K 16,466 at 14.22
14.5%
20 Apr 2021
Schor Chen President and CEO · indirect
Sold, plan not stated 2×
$197.68K 16,466 at 12.01
13.6%
6 Apr 2021
Schor Chen President and CEO · indirect
Sold, plan not stated 2×
$214.70K 16,466 at 13.04
12.8%
30 Mar 2021
Schor Chen President and CEO · indirect
Sold, plan not stated 4×
$211.64K 16,466 at 12.85
12.1%
16 Mar 2021
Schor Chen President and CEO · indirect
Sold, plan not stated 4×
$252.56K 16,466 at 15.34
11.5%
18 Dec 2019
Sold, plan not stated
$7.39M 6,161,531 at 1.20
74.4%
Sold half or more
13 Dec 2019
Sold, plan not stated
$255.80K 205,763 at 1.24
2.4%
12 Dec 2019
Sold, plan not stated
$482.32K 385,884 at 1.25
4.3%
10 Dec 2019
Sold, plan not stated
$423.66K 336,561 at 1.26
3.6%
15 Nov 2019
Sold, plan not stated
$661.94K 531,040 at 1.25
5.4%
30 Jan 2018
SILVERSTEIN JONATHAN Director · indirect
Bought
$8.00M 533,333 at 15.00
12.4%
First buy on file
30 Jan 2018
ORBIMED ADVISORS LLC Director · indirect
Bought
$8.00M 533,333 at 15.00
12.4%
First buy on file
30 Jan 2018
Bought
$3.50M 233,333 at 15.00
2.4%
First buy on file
Showing 1–42 of 42.